Curevac

• Initial Public Offering on the Nasdaq Global Market of 13,333,333 shares at a price of USD 16 per share, raising total gross proceeds of c. USD 213 million, which can increase to c. USD 245 million in case the over-allotment option is exercised in full
• Concurrent to the IPO, the company’s majority shareholder Mr. Dietmar Hopp has agreed to purchase €100 million of common shares at the IPO price per share in a private placement transaction
• The transaction generated significant demand from generalist and specialist investors globally, with the orderbook being multiple times covered despite the holiday season
  The majority of the proceeds will be used by CureVac to fund the clinical development of its revolutionary mRNA vaccine program against SARS-CoV-2 that it is advancing in response to the global COVID-19 pandemic
• Recognised for its Life Sciences sector knowledge and deep specialist investor inroads, Kempen & Co was selected to assist in attracting European and US specialist Life Sciences investors
• CureVac’s IPO marks the fourth IPO on Nasdaq in which Kempen & Co acted as an underwriter and the first in which it acted as a Passive Bookrunner
• In 2020 year to date, Kempen & Co has executed 14 transactions for European Life Sciences companies, raising a total of c. USD 2.4bn and including 6 transactions for Nasdaq listed companies

CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of prophylactic vaccines, cancer therapies, antibody therapies and the treatment of protein therapies. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

Over the past year, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

 

• Co-Manager in the USD 49.0 million US Public Offering by Centogene
• Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
• Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
• Co-Manager in the USD 600 million US Public Offering by Ascendis Pharma
• Financial advisor in the USD 253 million Immatics’ business combination with Arya Sciences Acquisition Corp.Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
• Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
• Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
• Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
• Co-Manager in the USD 862 million Global Offering by argenx
• Joint Bookrunner in the SEK 1,414 million Capital Increase by Oncopeptides
• Co-Manager in the USD 154 million Global Offering of DBV Therapeutics
• Joint Global Coordinator and Joint Bookrunner in the €19.0 million Capital Increase by Sequana Medical
• Lead Manager in the USD 557 million Global Offering by argenx
• Co-Manager in the USD 79.2 million US Public Offering by Merus
• Co-Manager in the USD 57.5 million Capital Increase by ProQR
• Co-Manager in the USD 150 million Nasdaq IPO of BioNTech
• Sole Bookrunner in the €9.0 million Capital Increase by MDxHealth
• Co-Manager in the USD 20.0 million Global Offering of Celyad